Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2012, Pages 289-294

  Xiao, Changting ^a   Dash, Satya ^a   Lewis, Gary F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apolipoprotein B 100; Apolipoprotein B 48; Cardiovascular disease; Chylomicron; Dipeptidyl peptidase 4; Dyslipidemia; Glucagon like peptide 1; Incretin based therapies; Triglyceride rich lipoprotein; Triglycerides; Type 2 diabetes; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HIGH DENSITY LIPOPROTEIN; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; METFORMIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; VILDAGLIPTIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DYSLIPIDEMIA; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PARTICLE SIZE; REVIEW; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; POSTPRANDIAL PERIOD; RECEPTORS, GLUCAGON;

EID: 84870276727     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512803530315     Document Type: Review

References (59)

1. Klein, R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995, 18(2), 258-268.
2. Ginsberg, H.N.; Zhang, Y.L.; Hernandez-Ono, A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res., 2005, 36(3), 232-240.
3. Miller, M.; Stone, N.J.; Ballantyne, C.; Bittner, V.; Criqui, M.H.; Ginsberg, H.N.; Goldberg, A.C.; Howard, W.J.; Jacobson, M.S.; Kris-Etherton, P.M.; Lennie, T.A.; Levi, M.; Mazzone, T.; Pennathur, S. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011, 123(20), 2292-2333.
4. Lewis, G.F.; Rader, D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96(12), 1221-1232.
5. Xiao, C.; Hsieh, J.; Adeli, K.; Lewis, G.F. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrinol. Metab., 2011, 301(3), E429-E446.
6. Taskinen, M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia, 2003, 46(6), 733-749.
7. Bansal, S.; Buring, J.E.; Rifai, N.; Mora, S.; Sacks, F.M.; Ridker, P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007, 298(3), 309-316.
8. Mero, N.; Malmstrom, R.; Steiner, G.; Taskinen, M. R.; Syvanne, M. Postprandial metabolism of apolipoprotein B-48-and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis, 2000, 150(1), 167-177.
9. Adeli, K.; Lewis, G.F. Intestinal lipoprotein overproduction in insulin-resistant states. Curr. Opin. Lipidol., 2008, 19(3), 221-228.
10. Drucker, D.J. The biology of incretin hormones. Cell Metab., 2006, 3(3), 153-165.
11. Drucker, D.J.; Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368(9548), 1696-1705.
12. Lovshin, J.A.; Drucker, D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol., 2009, 5(5), 262-269.
13. Nielsen, L.L.; Young, A.A.; Parkes, D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Pept., 2004, 117(2), 77-88.
14. Gentilella, R.; Bianchi, C.; Rossi, A.; Rotella, C.M. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes. Metab., 2009, 11(6), 544-556.
15. Amori, R.E.; Lau, J.; Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007, 298(2), 194-206.
16. Mudaliar, S.; Henry, R. R. Incretin therapies: effects beyond glycemic control. Eur. J. Intern. Med., 2009, 20(Suppl. 2), S319-S328.
17. Drucker, D.J.; Buse, J.B.; Taylor, K.; Kendall, D.M.; Trautmann, M.; Zhuang, D.; Porter, L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet, 2008, 372(9645), 1240-1250.
18. Buse, J.B.; Drucker, D.J.; Taylor, K.L.; Kim, T.; Walsh, B.; Hu, H.; Wilhelm, K.; Trautmann, M.; Shen, L.Z.; Porter, L.E. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 33(6), 1255-1261.
19. Buse, J.B.; Henry, R.R.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004, 27(11), 2628-2635.
20. Klonoff, D.C.; Buse, J.B.; Nielsen, L.L.; Guan, X.; Bowlus, C.L.; Holcombe, J.H.; Wintle, M.E.; Maggs, D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin., 2008, 24(1), 275-286.
21. Bergenstal, R.M.; Wysham, C.; MacConell, L.; Malloy, J.; Walsh, B.; Yan, P.; Wilhelm, K.; Malone, J.; Porter, L.E. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 2010, 376(9739), 431-439.
22. Varanasi, A.; Patel, P.; Makdissi, A.; Dhindsa, S.; Chaudhuri, A.; Dandona, P. Clinical use of liraglutide in type 2 diabetes, and its effects on cardiovascular risk factors. Endocr. Pract., 2012, 18(2), 104-145.
23. Bunck, M.C.; Corner, A.; Eliasson, B.; Heine, R.J.; Shaginian, R.M.; Wu, Y.; Yan, P.; Smith, U.; Yki-Jarvinen, H.; Diamant, M.; Taskinen, M.R. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis, 2010, 212(1), 223-229.
24. Kapitza, C.; Nauck, M.A.; Kim, D.; Trautmann, M.; Johns, D.; Festa, A. Long-term treatment with exenatide improved postprandial glyceric control and was associated with a shift from small to large HDL and LDL particles. Diabetologia, 2006, 49(Suppl.1), 140-141.
25. Blonde, L.; Klein, E.J.; Han, J.; Zhang, B.; Mac, S.M.; Poon, T.H.; Taylor, K.L.; Trautmann, M.E.; Kim, D.D.; Kendall, D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab., 2006, 8(4), 436-447.
26. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998, 317(7160), 703-713.
27. Meier, J.J.; Gethmann, A.; Gotze, O.; Gallwitz, B.; Holst, J.J.; Schmidt, W.E.; Nauck, M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49(3), 452-458.
28. Schwartz, E.A.; Koska, J.; Mullin, M.P.; Syoufi, I.; Schwenke, D.C.; Reaven, P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis, 2010, 212(1), 217-222.
29. Matikainen, N.; Manttari, S.; Schweizer, A.; Ulvestad, A.; Mills, D.; Dunning, B.E.; Foley, J.E.; Taskinen, M.R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49(9), 2049-2057.
30. Mari, A.; Nielsen, L.L.; Nanayakkara, N.; DeFronzo, R.A.; Ferrannini, E.; Halseth, A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm. Metab Res., 2006, 38(12), 838-844.
31. Mari, A.; Degn, K.; Brock, B.; Rungby, J.; Ferrannini, E.; Schmitz, O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care, 2007, 30(8), 2032-2033.
32. Foley, J.E.; Bunck, M.C.; Moller-Goede, D.L.; Poelma, M.; Nijpels, G.; Eekhoff, E.M.; Schweizer, A.; Heine, R.J.; Diamant, M. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011, 54(8), 1985-1991.
33. Mari, A.; Sallas, W.M.; He, Y.L.; Watson, C.; Ligueros-Saylan, M.; Dunning, B.E.; Deacon, C.F.; Holst, J.J.; Foley, J.E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves modelassessed beta-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2005, 90(8), 4888-4894.
34. Ahren, B.; Schweizer, A.; Dejager, S.; Villhauer, E.B.; Dunning, B.E.; Foley, J.E. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes. Metab., 2011, 13(9), 775-783.
35. Ahren, B.; Schweizer, A.; Dejager, S.; Dunning, B.E.; Nilsson, P.M.; Persson, M.; Foley, J.E. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2009, 94(4), 1236-1243.
36. Adiels, M.; Westerbacka, J.; Soro-Paavonen, A.; Hakkinen, A.M.; Vehkavaara, S.; Caslake, M.J.; Packard, C.; Olofsson, S.O.; Yki-Jarvinen, H.; Taskinen, M.R.; Boren, J. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia, 2007, 50(11), 2356-2365.
37. Duez, H.; Lamarche, B.; Uffelman, K.D.; Valero, R.; Cohn, J.S.; Lewis, G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol., 2006, 26(6), 1357-1363.
38. Lewis, G.F.; Uffelman, K.; Naples, M.; Szeto, L.; Haidari, M.; Adeli, K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology, 2005, 146(1), 247-255.
39. Malmstrom, R.; Packard, C.J.; Watson, T.D.; Rannikko, S.; Caslake, M.; Bedford, D.; Stewart, P.; Yki-Jarvinen, H.; Shepherd, J.; Taskinen, M.R. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler. Thromb. Vasc. Biol., 1997, 17(7), 1454-1464.
40. Malmstrom, R.; Packard, C.J.; Caslake, M.; Bedford, D.; Stewart, P.; Yki-Jarvinen, H.; Shepherd, J.; Taskinen, M.R. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes, 1998, 47(5), 779-787.
41. Pavlic, M.; Xiao, C.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes, 2010, 59(3), 580-587.
42. Longuet, C.; Sinclair, E.M.; Maida, A.; Baggio, L.L.; Maziarz, M.; Charron, M.J.; Drucker, D. J. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab., 2008, 8(5), 359-371.
43. Xiao, C.; Pavlic, M.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes, 2011, 60(2), 383-390.
44. Adiels, M.; Boren, J.; Caslake, M.J.; Stewart, P.; Soro, A.; Westerbacka, J.; Wennberg, B.; Olofsson, S.O.; Packard, C.; Taskinen, M.R. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol., 2005, 25(8), 1697-1703.
45. Prigeon, R.L.; Quddusi, S.; Paty, B.; D'Alessio, D.A. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am. J. Physiol. Endocrinol. Metab., 2003, 285(4), E701-E707.
46. Balas, B.; Baig, M.R.; Watson, C.; Dunning, B.E.; Ligueros-Saylan, M.; Wang, Y.; He, Y. L.; Darland, C.; Holst, J.J.; Deacon, C.F.; Cusi, K.; Mari, A.; Foley, J.E.; DeFronzo, R. A. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2007, 92(4), 1249-1255.
47. Azuma, K.; Radikova, Z.; Mancino, J.; Toledo, F.G.; Thomas, E.; Kangani, C.; Dalla, M.C.; Cobelli, C.; Holst, J.J.; Deacon, C.F.; He, Y.; Ligueros-Saylan, M.; Serra, D.; Foley, J.E.; Kelley, D.E. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2008, 93(2), 459-464.
48. Duez, H.; Smith, A.C.; Xiao, C.; Giacca, A.; Szeto, L.; Drucker, D.J.; Lewis, G.F. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. Endocrinology, 2009, 150(1), 56-62.
49. Tushuizen, M.E.; Diamant, M.; Heine, R.J. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad. Med. J., 2005, 81(951), 1-6.
50. Xiao, C.; Bandsma, R.H.; Dash, S.; Szeto, L.; Lewis, G.F. Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans. Arterioscler. Thromb. Vasc. Biol., 2012, 32(6), 1513-1519.
51. Parlevliet, E.T.; Schroder-van der Elst, J.P.; Corssmit, E.P.; Picha, K.; O'Neil, K.; Stojanovic-Susulic, V.; Ort, T.; Havekes, L.M.; Romijn, J.A.; Pijl, H. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J. Pharmacol. Exp. Ther., 2009, 328(1), 240-248.
52. Bjorkegren, J.; Packard, C.J.; Hamsten, A.; Bedford, D.; Caslake, M.; Foster, L.; Shepherd, J.; Stewart, P.; Karpe, F. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J. Lipid. Res., 1996, 37(1), 76-86.
53. Qin, X.; Shen, H.; Liu, M.; Yang, Q.; Zheng, S.; Sabo, M.; D'Alessio, D.A.; Tso, P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 288(5), G943-G949.
54. Farr, S.; Adeli, K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr. Opin. Lipidol., 2012, 23(1), 56-61.
55. Hsieh, J.; Longuet, C.; Baker, C.L.; Qin, B.; Federico, L.M.; Drucker, D.J.; Adeli, K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia, 2010, 53(3), 552-561.
56. Fadini, G.P.; Avogaro, A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul. Pharmacol., 2011, 55(1-3), 10-16.
57. Wasada, T.; McCorkle, K.; Harris, V.; Kawai, K.; Howard, B.; Unger, R.H. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J. Clin. Invest., 1981, 68(4), 1106-1107.
58. Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Ferrannini, E.; Holman, R.R.; Sherwin, R.; Zinman, B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009, 32(1), 193-203.
59. Cernea, S.; Raz, I. Therapy in the early stage: incretins. Diabetes Care, 2011, 34(Suppl. 2), S264-S271